Medexus Schedules First Fiscal Quarter 2025 Conference Call
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has announced a conference call scheduled for August 8, 2024, at 8:00 am Eastern Time to discuss the company's financial results for the first fiscal quarter ended June 30, 2024. The company plans to file its financial statements and MD&A after market close on August 7, 2024.
Investors can participate in the call using the provided toll-free numbers for Canadian and U.S. callers, or the international number. A live webcast will be available on Medexus's corporate website. A replay of the call will be accessible until August 15, 2024, and a webcast replay will be available until August 8, 2025.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) ha annunciato una conferenza telefonica prevista per 8 agosto 2024, alle 8:00 ora orientale per discutere i risultati finanziari dell'azienda per il primo trimestre fiscale conclusosi il 30 giugno 2024. L'azienda prevede di presentare i suoi stati finanziari e il MD&A dopo la chiusura del mercato il 7 agosto 2024.
Gli investitori possono partecipare alla chiamata utilizzando i numeri verdi forniti per i chiamanti canadesi e statunitensi, o il numero internazionale. Sarà disponibile una trasmissione in diretta sul sito web aziendale di Medexus. Una registrazione della chiamata sarà accessibile fino al 15 agosto 2024, e una registrazione della trasmissione sarà disponibile fino all'8 agosto 2025.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) ha anunciado una llamada de conferencia programada para el 8 de agosto de 2024, a las 8:00 a.m., hora del Este para discutir los resultados financieros de la empresa del primer trimestre fiscal finalizado el 30 de junio de 2024. La empresa planea presentar sus estados financieros y MD&A después del cierre del mercado el 7 de agosto de 2024.
Los inversores pueden participar en la llamada utilizando los números gratuitos proporcionados para los llamantes canadienses y estadounidenses, o el número internacional. Se ofrecerá una transmisión en vivo en el sitio web corporativo de Medexus. Una repetición de la llamada estará accesible hasta el 15 de agosto de 2024, y una repetición de la transmisión estará disponible hasta el 8 de agosto de 2025.
메두스 제약(Medexus Pharmaceuticals, TSX: MDP) (OTCQX: MEDXF)은 2024년 8월 8일 동부 표준시 기준 오전 8시에 회사의 2024년 6월 30일 종료된 첫 번째 회계 분기 재무 결과를 논의하기 위해 예정된 컨퍼런스 콜을 발표했습니다. 회사는 2024년 8월 7일 장 마감 후 재무 제표와 MD&A를 제출할 계획입니다.
투자자는 제공된 캐나다 및 미국 호출자를 위한 무료 전화번호 또는 국제 전화를 사용하여 통화에 참여할 수 있습니다. Medexus의 기업 웹사이트에서 실시간 웹캐스트도 제공될 예정입니다. 이번 통화의 재생은 2024년 8월 15일까지 접근 가능하며, 웹캐스트 재생은 2025년 8월 8일까지 제공될 것입니다.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) a annoncé une conférence téléphonique prévue pour le 8 août 2024 à 8h00, heure de l'Est, afin de discuter des résultats financiers de l'entreprise pour le premier trimestre fiscal terminé le 30 juin 2024. L'entreprise prévoit de déposer ses états financiers et son MD&A après la clôture du marché le 7 août 2024.
Les investisseurs peuvent participer à l'appel en utilisant les numéros sans frais fournis pour les appelants canadiens et américains, ou le numéro international. Une diffusion en direct sera disponible sur le site Web de Medexus. Un enregistrement de l'appel sera accessible jusqu'au 15 août 2024, et un enregistrement en ligne sera disponible jusqu'au 8 août 2025.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) hat eine Telefonkonferenz angesetzt für 8. August 2024, um 8:00 Uhr Eastern Time, um die finanziellen Ergebnisse des Unternehmens für das ersten Geschäftsjahr des am 30. Juni 2024 endete zu besprechen. Das Unternehmen plant, seine Finanzberichte und den MD&A nach Börsenschluss am 7. August 2024 einzureichen.
Investoren können an dem Anruf teilnehmen, indem sie die bereitgestellten gebührenfreien Nummern für kanadische und US-Anrufer oder die internationale Nummer nutzen. Es wird einen Live-Stream auf der Unternehmenswebsite von Medexus geben. Eine Aufzeichnung des Anrufs ist bis zum 15. August 2024 verfügbar, und eine Webcast-Wiederholung wird bis zum 8. August 2025 verfügbar sein.
- None.
- None.
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, August 8, 2024 to discuss Medexus's results for its first fiscal quarter ended June 30, 2024. Medexus expects to file its financial statements and MD&A after markets close on August 7, 2024.
To participate in the call, please dial the following numbers:
888-506-0062 (toll-free) for Canadian and U.S. callers
+1 973-528-0011 for international callers
Access code: 570092
A live webcast of the call will be available on the Investors section of Medexus's corporate website or at the following link:
https://www.webcaster4.com/Webcast/Page/2010/50994
A replay of the call will be available approximately one hour following the end of the call through Thursday, August 15, 2024. To access the replay, please dial the following numbers -
877-481-4010 for Canadian and U.S. callers
+1 919-882-2331 for international callers
Conference ID: 50994
A replay of the webcast will be available on the Investors section of Medexus's corporate website until Friday, August 8, 2025.
About Medexus
Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.com.
Contacts
Ken d'Entremont | CEO, Medexus Pharmaceuticals
Tel: 905-676-0003 | Email: ken.dentremont@medexus.com
Brendon Buschman | CFO, Medexus Pharmaceuticals
Tel: 416-577-6216 | Email: brendon.buschman@medexus.com
Forward-looking statements
Certain statements made in this news release contain forward-looking information within the meaning of applicable securities laws (forward-looking statements). The words "anticipates", "believes", "expects", "will", "plans", "potential", and similar words, phrases, or expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words, phrases, or expressions. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions, and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. Medexus cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Material risk factors include, but are not limited to, those set out in Medexus's materials filed with the Canadian securities regulatory authorities from time to time, including Medexus's most recent annual information form and management's discussion and analysis. Accordingly, undue reliance should not be placed on these forward-looking statements, which are made only as of the date of this news release. Other than as specifically required by law, Medexus undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/218214
FAQ
When is Medexus Pharmaceuticals (MEDXF) hosting its Q1 2025 earnings call?
What period will Medexus Pharmaceuticals (MEDXF) Q1 2025 results cover?
When will Medexus Pharmaceuticals (MEDXF) file its Q1 2025 financial statements?
How long will the replay of Medexus Pharmaceuticals (MEDXF) Q1 2025 earnings call be available?
